Hubbry Logo
CelgeneCelgeneMain
Open search
Celgene
Community hub
Celgene
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Celgene
Celgene
Celgene
View on Wikipedia
from Wikipedia

Celgene Corporation, headquartered in Summit, New Jersey, was a pharmaceutical company that produced cancer and immunology drugs. Its primary products were Revlimid (lenalidomide), which is used in the treatment of multiple myeloma (63% of 2018 revenues); Pomalyst and Imnovid (Pomalidomide), also used in the treatment of multiple myeloma (13% of 2018 revenues); and Otezla (Apremilast), used in the treatment of psoriasis (11% of 2018 revenues).[1] In 2018, 66% of the company's revenues came from the United States.[1] In 2019, the company was acquired by Bristol Myers Squibb (BMS); as part of the acquisition, Otezla was sold to Amgen.

Key Information

History

[edit]

Celgene was originally a unit of Celanese. In 1986, Celanese completed the corporate spin-off of Celgene following the merger of Celanese with American Hoechst.[2][3]

In August 2000, Celgene acquired Signal Pharmaceuticals, Inc., a privately held company that developed pharmaceuticals to regulate disease-related genes.[4] Signal Pharmaceuticals was rebranded as Celgene Research San Diego.[5]

In December 2002, Celgene acquired Anthrogenesis, a privately held New Jersey–based biotherapeutics company and cord blood banking business, which is developing technology for the recovery of stem cells from placental tissues following the completion of full-term successful pregnancies. Anthrogenesis was rebranded as Celgene Cellular Therapeutics.[6]

In 2006, Celgene certified McKesson Specialty, a specialty pharmacy, as one of a group of pharmacies contracted to launch lenalidomide (Revlimid). As a specialty drug, lenalidomide is only available through the a distribution network consisting of specialty pharmacies contracted by the company.[7]

In March 2008, Celgene acquired Pharmion Corporation for $2.9 billion.[8]

In January 2010, Celgene acquired Gloucester Pharmaceuticals.[9]

In June 2010, Celgene agreed to acquire Abraxis BioScience for $2.9 billion, which produced Abraxane, for the treatment of cancer.[10][11]

In November 2011, Celgene relocated its United Kingdom headquarters from Windsor, Berkshire, to Stockley Park, near Heathrow airport which is also the home of GlaxoSmithKline's UK operations.[12]

In January 2012, Celgene agreed to acquire Avila Therapeutics, a privately held biotechnology company for $925 million, with $350 million in cash.[13]

In December 2013, Celgene and OncoMed joined a cancer Stem cell therapy development agreement with demcizumab and five other biologics from OncoMed's pipeline.[14]

In October 2014, Sutro Biopharma entered into an agreement with Celgene Corporation to discover and develop multispecific antibodies and antibody drug conjugates (ADCs).[15] This followed the December 2012 collaboration between the two companies and focused on the field of immuno-oncology.[16]

In April 2015, Celgene announced a collaboration with AstraZeneca, worth $450 million, to study their Phase III immuno-oncology drug candidate MEDI4736.[17]

That same month, Celgene exercised its option to acquire Quanticel for up to $485 million to enhance its cancer drug pipeline.[18] Celgene had invested in Quanticel in April 2011.[19]

In June 2015, Celgene exercised its option to license Lyceras RORgamma agonist portfolio for up to $105 million to develop its Phase I lead compound LYC-30937 for the treatment of inflammatory bowel disease. The licensing opportunity gave Celgene the option to acquire Lycera.[20][21]

In July 2015, the company announced it would acquire Receptos for $7.2 billion in a move to strengthen the company's inflammation and immunology areas.[22]

In May 2016, the company announced it would launch partnership with Agios Pharmaceuticals, developing metabolic immuno-oncology therapies.[23]

In October 2016, the company acquired EngMab AG for $600 million.[24][25]

In January 2017, the company announced it would acquire Delinia for up to $775 million, increasing the company's autoimmune disease therapy offerings.[26]

In January 2018, Celgene announced it would acquire Impact Biomedicines for $7 billion, adding fedratinib, a kinase inhibitor with potential to treat myelofibrosis.[27]

In March 2018, the company acquired Juno Therapeutics for $9 billion.[28][29] That month, the company paid $101 million to partner with Vividion on the discovery of small molecules that hit hard-to-drug proteins.[30]

In January 2019, the company committed to pay up to $980 million to license TRPH-395, a small molecule that targets protein-protein interactions and epigenetic regulation in leukemia and lymphoma.[31]

In March 2019, the company partnered with Exscientia on three of its drug programs targeting oncology and autoimmunity.[32]

In November 2019, Bristol-Myers Squibb (BMS) acquired the company for $74 billion in the largest pharmaceutical acquisition to date.[33][34][35] As part of the acquisition, Amgen acquired the Otezla drug program from Celgene for $13.4 billion.[36][37] Activist investor Starboard Value opposed the deal, nominating five alternative potential directors on the Bristol-Myers board;[38] however, it retracted its opposition after Institutional Shareholder Services and Glass Lewis supported the transaction and it appeared to have enough shareholder support.[39]

Company origin and acquisition history

[edit]

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

  • Celgene (Spun off from Celanese in 1986, acquired by Bristol-Myers Squibb in 2019)
    • Signal Pharmaceuticals, Inc (Acq 2000)
    • Anthrogenesis (Acq 2002)
    • Pharmion Corporation (Acq 2008)
    • Gloucester Pharmaceuticals (Acq 2009)
    • Abraxis BioScience Inc (Acq 2010)
    • Avila Therapeutics, Inc (Acq 2012)
    • Quanticel (Acq 2015)
    • Receptos (Acq 2015)
    • EngMab AG (Acq 2016)
    • Delinia (Acq 2017)
    • Impact Biomedicines (Acq 2018)
    • Juno Therapeutics (Acq 2018)
      • AbVitro (Acq 2016)
      • RedoxTherapies (Acq 2016)

Management history

[edit]

In March 2016, Bob Hugin, the company's long serving CEO, retired from his position and took the role of executive chairman. Bob Hugin was succeeded in the CEO role by Mark Alles. At the same time, Jacqualyn Fouse was named as the company's president and COO; Fouse had joined the company in 2010 as the CFO. Effective June 30, 2017, Dr. Fouse resigned and was succeeded by Scott Smith, president of the company's Global Inflammation & Immunology Franchise, who joined the company in 2008.[40]

Finances

[edit]

For the fiscal year 2017, Celgene reported earnings of US$2.539 billion, with an annual revenue of US$13.003 billion, an increase of 15.8% over the previous fiscal cycle.[41]

Year Revenue
in mil. USD$ 		Net income
in mil. USD$ 		Total Assets
in mil. USD$ 		Employees
2005 537 64 1,258
2006 899 69 2,736
2007 1,406 226 3,611
2008 2,255 −1,534 4,445
2009 2,690 777 5,389
2010 3,626 881 10,177
2011 4,842 1,318 10,006
2012 5,507 1,456 11,734
2013 6,494 1,450 13,378 5.100
2014 7,670 2,000 17,340 6,012
2015 9,256 1,602 26,964 6,971
2016 11,229 1,999 28,086 7,132
2017 13,003 2,940 30,141 7,467

Products

[edit]

Major products included Revlimid (lenalidomide) and Pomalyst (pomalidomide) and the immunology drug Otezla (apremilast).

Product Portfolio
Brand Name Drug Name(s) Indication Date Approved (USA)[42] Partner
Alkeran melphalan palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary 01-17-1964 GlaxoSmithKline
Alkeran melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate 11-18-1992 GlaxoSmithKline
Thalomid thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences 07-16-1998  
Thalomid thalidomide (in combination with dexamethasone) treatment of patients with newly diagnosed multiple myeloma 05-25-2006 GlaxoSmithKline
Focalin dexmethylphenidate hydrochloride CII attention deficit hyperactivity disorder (ADHD) in children and adolescents 11-13-2001 Novartis
Focalin XR dexmethylphenidate hydrochloride CII attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults 05-26-2005 Novartis
Vidaza azacitidine treatment of patients with refractory anemia, chronic myelomonocytic leukemia 05-19-2004  
Revlimid lenalidomide transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities 12-27-2005  
Revlimid lenalidomide (in combination with dexamethasone) treatment of multiple myeloma patients who have received at least one prior therapy 06-29-2006  
[edit]

In July 1998, Celgene received approval from the FDA to market Thalomid for the acute treatment of the cutaneous manifestations of moderate to severe ENL.[43]

In April 2000, Celgene reached an agreement with Novartis Pharma AG to license d-MPH, Celgene's chirally pure version of RITALIN. The FDA subsequently granted approval to market d-MPH, or Focalin, in November 2001.[44]

In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Focalin XR was later launched by Celgene and Novartis in 2005.[45]

In May 2006, Celgene received approval for Thalomid in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.

In June 2007, Celgene received full marketing authorization for Revlimid in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the European Commission.

Pipeline

[edit]
  • Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). Ozanimod causes lymphocyte retention in lymphoid tissues. The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve the reduction of lymphocyte migration into the central nervous system. Ozanimod is in development for immune-inflammatory indications including ulcerative colitis and Crohn's disease.[46]
  • Celgene developed several products within several areas of research (MM, MDS, AML, Lymphoma, CLL, Beta-Thalassemia, Myelofibrosis, Solid Tumors, Inflammation & Immunology.[1]

Litigation

[edit]

Antitrust allegations

[edit]

In 2009, Dr. Reddy's Laboratories requested, and Celgene refused to provide, a samples of Celgene's anticancer drug THALOMID (thalidomide). Dr. Reddy's Laboratories sought the material for bioequivalency studies required to bring its own, generic, version of thalidomide to market. In response to the refusal, Dr. Reddy's Laboratories filed a Citizen's Petition with the FDA asking the Agency to adopt procedures that would ensure generic applicants the right to buy sufficient samples to perform bioequivalence testing of drugs that were subject to REMS distribution restrictions.

Celgene denied that it had behaved anti-competitively, arguing that the legislative history strongly suggested that Congress considered and rejected a proposed guaranteed access procedure like the one proposed by Dr. Reddy's. Celgene further argued that requiring innovator companies to sell their products to potential generic competitors would violate its intellectual property rights and subject it to liability risks in the event that patients were harmed in Dr. Reddy's studies.

In 2018, Celgene was at the top of a list of companies that the FDA identified as refusing to release samples to competitors to create generics.[47]

Generic manufacturer Lannett Company initiated antitrust litigation that accused Celgene of using its REMS for THALOMID (thalidomide) to violate the anti-monopolization provisions of the Sherman Act. In early 2011, the district court denied Celgene's motion to dismiss. The case was set for trial beginning in February 2012, but the parties settled before the trial began, thereby postponing further judicial review of antitrust claims premised on alleged abuse of REMS distribution restrictions.[48]

Fraud allegations

[edit]

In July 2017, Celgene agreed to pay $280 million to government agencies to settle allegations that it caused the submission of false claims or fraudulent claims for non-reimbursable uses of its drugs Revlimid and Thalomid to Medicare and state Medicaid programs.[49] In its July 2017 10-Q, Celgene disclosed that it resolved the matter in full for $315 million, including fees and expenses.[50] The case was brought under the False Claims Act by Beverly Brown, a former Celgene sales representative.[51]

Price increases

[edit]

Celgene and BMS repeatedly raised the price of its primary drug, Revlimid, from $218 per pill in 2005 to $892 in 2023, while the cost to manufacture remained approximately $0.25 per pill throughout this period.[52]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Celgene

View on Grokipedia
from Grokipedia
Celgene Corporation was an integrated global biopharmaceutical company headquartered in Summit, New Jersey, primarily engaged in the discovery, development, and commercialization of therapies for cancer and immunology. Founded in 1986 as a spin-off from the chemical firm Celanese Corporation by Robert Hariri and Sol Barer, Celgene initially pursued microbial technologies for toxic waste remediation before shifting to biotechnology focused on immunomodulatory agents, including thalidomide derivatives like Thalomid and its successor Revlimid. Revlimid, approved for multiple myeloma and other hematologic malignancies, emerged as a cornerstone product driving annual revenues exceeding $10 billion at peak, underscoring Celgene's advancements in oncology while fueling debates over pricing sustainability and market exclusivity tactics such as Risk Evaluation and Mitigation Strategies (REMS) that delayed generic entry. The company expanded through acquisitions like Juno Therapeutics in 2018 to bolster cellular immunotherapies, yet encountered controversies including allegations of channeling funds through patient assistance charities to induce copay coverage for its high-cost drugs and antitrust suits claiming monopolization of Thalomid and Revlimid markets, resulting in settlements such as $55 million in 2019. In January 2019, Bristol-Myers Squibb announced its $74 billion acquisition of Celgene, completed later that year, merging portfolios to form a leading entity in innovative biopharmaceuticals with deepened capabilities in immunology and hematology-oncology.

History

Founding and Early Development

Celgene Corporation was established in 1986 as a spin-off from a biotechnology unit of Celanese Corporation, which had been formed in 1980. Headquartered initially in Warren, New Jersey, the company focused on applying biotechnology to industrial processes, particularly bioremediation, where it developed microorganisms capable of degrading environmental pollutants such as toluene. In 1987, Celgene completed its initial public offering, providing capital for early research efforts, though revenues remained modest at $2.3 million in 1988. By the early 1990s, Celgene pivoted from to pharmaceutical development, emphasizing small-molecule immunomodulatory agents. This shift was driven by the acquisition of exclusive worldwide rights to in 1992, a compound infamous for causing severe birth defects in the and but showing potential in treating inflammatory conditions through inhibition and immune modulation. The company discontinued its bioremediation operations in 1994 to concentrate resources on this high-risk strategy, despite ethical and regulatory opposition from thalidomide victims' groups and initial FDA scrutiny over safety protocols. Celgene's persistence paid off with the U.S. Food and Drug Administration's approval of Thalomid () on July 16, 1998, for the treatment of leprosum, a painful complication of . This marked the firm's first commercial product, implemented under a stringent System for Thalidomide Education and Prescribing Safety (STEPS) program to prevent fetal exposure. Early years were marked by ongoing annual losses and R&D challenges, as the company invested heavily in derivatives of to expand into indications, laying the groundwork for future immunomodulatory drug classes amid limited initial revenues.

Expansion Through Acquisitions and Milestones

Celgene's growth in the mid-2000s was markedly propelled by the U.S. Food and Drug Administration's approval of Revlimid () on December 27, 2005, for treatment of in patients who had received at least one prior therapy, in combination with dexamethasone. This immunomodulatory rapidly became a cornerstone of the company's portfolio, contributing to total revenues of $181.8 million in —primarily driven by early Revlimid sales—and escalating to billions annually by the 2010s, with U.S. net revenues alone surpassing $6.5 billion in 2018 as label expansions broadened its use in newly diagnosed and maintenance settings. Clinical data from pivotal trials demonstrated Revlimid's role in extending compared to , underpinning its commercial success through demonstrated efficacy in a high-unmet-need indication. Strategic acquisitions further diversified Celgene's pipeline and therapeutic focus. In , the company acquired Abraxis BioScience for $2.9 billion in cash and stock, securing Abraxane (paclitaxel protein-bound particles for injectable suspension), an approved therapy utilizing albumin-bound technology for , which complemented Revlimid by expanding solid tumor capabilities and adding manufacturing synergies. This move integrated Abraxis's proprietary nab technology, enabling pipeline enhancements in areas like and pancreatic cancers without relying on novel chemical entities alone. By 2015, Celgene pursued immunology expansion through its $7.2 billion acquisition of Receptos, yielding —a once-daily oral (S1P) receptor modulator in late-stage development for relapsing and —thereby bolstering the company's position in immune-mediated diseases amid competitive pressures in . These deals exemplified augmentation via targeted buys of complementary assets, yielding diversified revenue streams from both marketed products and investigational candidates. Key milestones in the included label expansions for Revlimid, such as FDA approval in 2015 for frontline in combination with , , and , which correlated with peak annual sales exceeding $9 billion globally by 2017, reflecting market validation of iterative innovation over static portfolios. Partnerships, such as the 2018 acquisition of for $9 billion to advance CAR-T therapies like JCAR017, marked entry into cellular immunotherapies, while international commercialization efforts scaled Revlimid access across and , with ex-U.S. sales growing to contribute over 30% of total revenues by the late . These developments underscored Celgene's scaling through organic advancements and accretive deals, prioritizing therapeutic breadth in and to capture value from clinical differentiation.

Acquisition by Bristol-Myers Squibb

Bristol-Myers Squibb announced its acquisition of Celgene on January 3, 2019, in a transaction valued at approximately $74 billion, consisting of cash and stock. The deal closed on November 20, 2019, following shareholder approvals from both companies on April 12, 2019. This merger positioned the combined entity as a leading player in and by integrating Celgene's portfolio of approved therapies and pipeline candidates with Bristol-Myers Squibb's existing assets. The strategic rationale centered on enhancing synergies through the combination of Celgene's expertise in cell therapies, such as CAR-T programs from its Juno acquisition, with Bristol-Myers Squibb's checkpoint inhibitors like Opdivo. Executives projected $2.5 billion in annual cost synergies from operational efficiencies, alongside revenue growth from a diversified portfolio featuring nine products each generating over $1 billion in peak sales potential. The merger aimed to accelerate innovation in immuno-oncology, addressing competitive pressures in solid tumors and hematologic malignancies without relying on unsubstantiated monopoly concerns. Regulatory clearance from the U.S. was granted on November 15, 2019, conditioned on the divestiture of Celgene's drug Otezla to to preserve competition in that market segment. No broader antitrust divestitures were required for assets, reflecting the agencies' assessment that the combination would not substantially lessen competition in core therapeutic areas. Post-merger integration yielded tangible outcomes, including accelerated regulatory approvals for Celgene-originated CAR-T therapies like Breyanzi and Abecma, contributing to growth in the combined company's oncology franchise. By 2025, the growth portfolio—encompassing key Celgene legacies such as Revlimid and Orencia—reported 16% to 18% year-over-year revenue increases in early quarters, supporting raised full-year guidance to $46.5 billion to $47.5 billion. These results, alongside realized cost synergies exceeding initial targets, validated the transaction's value creation, countering narratives of stagnation with evidence of sustained R&D momentum and portfolio diversification.

Leadership and Governance

Key Executives and Management Changes

Sol Barer co-founded Celgene in 1986 as a spin-off from Corporation and served as its president and from 1994 to 2006, during which the company shifted from chemical manufacturing toward development, laying groundwork for later growth through targeted therapies. Barer ascended to in May 2006, succeeding John W. Jackson, who had led since 1996, and under Barer's tenure, Celgene pursued strategic acquisitions and expansions that bolstered its market position. He transitioned to executive chairman in 2010, continuing to influence direction until 2011 while the firm navigated early regulatory scrutiny over drug promotion practices. Robert J. Hugin succeeded Barer as CEO in early 2011, bringing internal operational expertise from his roles in sales and international expansion; his leadership emphasized scaling commercial operations amid rising legal challenges, including off-label marketing allegations resolved through a $280 million settlement in 2017 without admitting liability. Under Hugin, Celgene intensified investments, with annual R&D expenditures surpassing $3 billion by the mid-2010s, reflecting a commitment to pipeline diversification despite compliance enhancements like bolstered functions post-settlement. These adaptations addressed federal probes into risk evaluation and mitigation strategies (REMS) for certain drugs, prioritizing merit-driven hires in legal and ethics roles to mitigate recurrence. Mark J. Alles, who joined Celgene in 2004 and rose through commercial , became CEO in March 2016 following Hugin's shift to executive chairman, steering the company through its $74 billion acquisition by Bristol-Myers Squibb announced in 2019 and completed in November 2019. Alles's tenure focused on integrating global operations and defending the merger against antitrust concerns, culminating in his departure post-closing while maintaining elevated R&D commitments inherited from prior executives. This succession pattern underscored a continuity in technically proficient , enabling sustained investments amid external pressures, though regulatory filings later highlighted ongoing REMS-related litigation risks.

Board and Strategic Direction

The of Celgene Corporation, following the company's in , incorporated members with specialized expertise in and to refine its strategic emphasis on and over broader pharmaceutical diversification. This composition shift supported a targeted pipeline development, prioritizing immunomodulatory agents and cellular therapies in high-unmet-need areas like and . Under board guidance, Celgene pursued aggressive merger and acquisition strategies to bolster its portfolio, exemplified by the 2015 acquisition of Receptos for $7.2 billion, which integrated apremilast (Otezla) and advanced the company's position in immune-inflammatory diseases. This deal aligned with a broader M&A prioritization that emphasized assets with strong clinical data and market potential, contributing to sustained revenue growth from specialized therapeutics. Concurrently, the board oversaw patent lifecycle management tactics, including the accumulation of 14 patents tied to risk evaluation and mitigation strategies (REMS) for blockbuster drugs like Revlimid and Thalomid, which delayed generic entry and preserved exclusivity periods. Board oversight extended to risk mitigation in litigation-heavy environments, particularly around patent challenges to Revlimid, where strategic settlements—such as the one with —minimized disruptions while enabling focus on core growth drivers and culminating in the $74 billion acquisition by Bristol-Myers Squibb in 2019. This approach balanced aggressive expansion with prudent governance, prioritizing long-term shareholder returns through disciplined capital allocation amid regulatory and competitive pressures.

Scientific and Medical Innovations

Core Technologies and Research Focus

Celgene's primary proprietary platform centered on immunomodulatory imide drugs (IMiDs), evolved from analogs that selectively bind to (CRBN), a substrate receptor in the Cullin-Ring E3 complex (CRL4CRBN). This binding induces ubiquitination and proteasomal degradation of zinc-finger transcription factors such as () and IKZF3 (Aiolos), disrupting cancer cell survival signaling and promoting immune-mediated anti-tumor effects through modulation and T-cell activation. Empirical preclinical and early demonstrated causal degradation of these neo-substrates correlating with reduced tumor burden in hematologic malignancies, distinguishing IMiDs from non-degrading inhibitors by leveraging endogenous machinery. In cellular therapies, Celgene pursued adoptive T-cell engineering via a March 2013 global collaboration with bluebird bio, focusing on chimeric antigen receptor (CAR) T-cell constructs genetically modified ex vivo to express tumor-specific receptors, such as those targeting B-cell maturation antigen (BCMA). This approach harnesses redirected T-cell cytotoxicity against refractory B-cell neoplasms by amplifying epitope-specific killing while minimizing off-target effects through controlled expansion and infusion protocols. The partnership emphasized scalable lentiviral transduction for CAR integration, enabling persistence and proliferation in vivo that causally linked to deepened remissions in preclinical models of antigen-expressing tumors. Celgene further innovated in targeted protein degradation beyond IMiDs, developing E3 ligase modulators (CELMoDs)—small-molecule glues that expand substrate specificity for degrading disease-associated proteins—and heterobifunctional degraders via alliances like the 2018 pact with Vividion Therapeutics. These modalities exploit proximity-induced ubiquitination to eliminate "undruggable" targets, such as transcription factors resistant to occupancy-based inhibition, with confirming pocket-binding affinities that drive selective and downstream phenotypic responses in models. Celgene's R&D investments, peaking at 37% of 2018 revenue, underpinned these platforms' mechanistic validation through iterative screening and structural optimization.

Breakthrough Therapies and Approvals

Celgene's Vidaza (azacitidine) received FDA approval on May 19, 2004, as the first hypomethylating agent for subcutaneous or intravenous treatment of myelodysplastic syndromes (MDS) in patients ineligible for stem cell transplant, addressing a previously unmet need in this orphan disease with limited prior options beyond supportive care. Clinical trials, including the AZA-001 study, demonstrated a median overall survival (OS) of 24.4 months with Vidaza versus 15 months with conventional care regimens (conventional care failure 55%, low-dose cytarabine 29%, or best supportive care 16%), representing a hazard ratio (HR) of 0.58 and a 62% reduction in mortality risk, with complete response rates of 7% and partial responses of 16%. This approval leveraged orphan drug designation, incentivizing development for rare hematologic malignancies where causal mechanisms of DNA hypomethylation directly targeted aberrant epigenetic regulation in MDS blasts, yielding durable responses without reliance on cytotoxic chemotherapy. Revlimid (), an immunomodulatory derivative of , was granted FDA approval on December 27, 2005, initially for transfusion-dependent in low- or intermediate-1-risk MDS with deletion 5q cytogenetic abnormality, marking the first for this subtype based on phase 2 data showing transfusion independence in 76% of patients (median duration 41 weeks). Extended to on , 2006, in with dexamethasone for patients with at least one prior , Revlimid exhibited superior progression-free survival (PFS) of 11.1 months versus 4.7 months with dexamethasone alone (HR 0.55) in the MM-009 and MM-010 trials, alongside overall response rates exceeding 60%; long-term data indicate 2- to 3-fold OS extensions compared to pre-novel agent eras (historical medians ~24-30 months versus 70+ months in transplant-ineligible patients with continuous lenalidomide-dexamethasone). These outcomes stem from lenalidomide's multifaceted mechanism—cereblon-mediated ubiquitination of transcription factors, enhanced NK cell activity, and anti-angiogenic effects—empirically validated against standards lacking such immune-modulating potency. status facilitated rapid development, prioritizing causal efficacy in settings over broad-market therapies. Pomalyst (pomalidomide) earned FDA accelerated approval on February 8, 2013, for relapsed/refractory after at least two prior regimens, including and , based on phase 2 trials showing median PFS of 4.0 months versus 1.9 months with pomalidomide-placebo plus low-dose dexamethasone (HR 0.48) and objective response rates of 31% versus 10%. Subsequent designation in May 2019 for AIDS-related and HIV-negative Kaposi after highly active antiretroviral therapy failure or systemic led to accelerated approval on May 15, 2020, supported by phase 1/2 data with overall response rates of 60% (HIV-positive) and 43% (HIV-negative), sustained for medians of 20.3 and 37.0 months, respectively, addressing a rare malignancy with high unmet need. Like predecessors, pomalidomide's cereblon-binding affinity drives targeted protein degradation, empirically outperforming single-agent salvage in heavily pretreated cohorts where causal resistance pathways predominate. These approvals collectively enabled outpatient administration for millions of patients worldwide with hematologic malignancies, shifting paradigms from inpatient to targeted oral regimens that empirically reduce long-term hospitalization burdens through extended event-free , as evidenced by real-world registries confirming OS gains in diverse populations without by indication bias in controlled trials. incentives under the 1983 Act were instrumental, fostering investment in low-prevalence indications where market-driven might deter causal validation via large-scale randomized data.

Products and Commercial Portfolio

Oncology and Hematology Drugs

Revlimid (lenalidomide), a thalidomide analog that modulates the immune system by binding cereblon to ubiquitinate transcription factors inhibiting myeloma cell growth, became Celgene's cornerstone oncology drug. The FDA approved it on December 16, 2005, for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) after prior erythropoiesis-stimulating agent failure, based on phase II trials showing 76% transfusion independence rates lasting over 1 year. In June 2006, approval expanded to relapsed or refractory multiple myeloma (MM) in combination with dexamethasone, with pivotal trials demonstrating overall response rates (ORR) of 60-75% versus 19% for dexamethasone alone, alongside superior progression-free survival (PFS) of 11.1 months versus 4.7 months. Further label expansions included frontline MM with dexamethasone and melphalan/prednisone (2009), post-autologous stem cell transplant maintenance (2017, based on meta-analysis of three trials showing 52% PFS improvement), and rituximab combination for follicular and marginal zone lymphoma (2019, ORR 78%). Despite black-box warnings for embryofetal toxicity (requiring REMS program), hematologic toxicity (neutropenia in 50-60% of MM patients), and thromboembolism (risk mitigated by prophylaxis), risk-benefit analyses from randomized trials affirm net survival gains, with overall survival (OS) extensions of 7-10 months in MM subsets. Global sales peaked at $9.6 billion in 2018, driven by these expanded indications enabling broader frontline and maintenance use rather than isolated pricing effects. Pomalyst (pomalidomide), another immunomodulatory agent targeting similar pathways with enhanced potency over in resistant cells, received FDA approval on February 8, 2013, for relapsed/refractory MM after at least two prior therapies including and . Pivotal phase II trial data supported this, yielding an ORR of 29% with low-dose dexamethasone (versus 7% monotherapy), median duration of response 17.6 months, and PFS of 4 months in heavily pretreated patients; OS reached 12.7 months, establishing in -refractory settings where alternatives yielded <10% responses. and risks mirror Revlimid's profile, with trials emphasizing prophylaxis to sustain benefits. Abraxane (nab-paclitaxel), an albumin-bound formulation of avoiding Cremophor solvent toxicity, was integrated into Celgene's portfolio following the 2010 Abraxis acquisition. Initially FDA-approved in 2005 for (MBC) after combination failure, showing 33% ORR versus 19% for solvent-based at equivalent doses (260 mg/m²), with superior tolerability enabling higher dosing and fewer hypersensitivity reactions. Expansions included first-line non-small cell (NSCLC) with (2012, ORR 33% versus 25%, PFS benefit in squamous ), and metastatic with (2013, OS 8.5 versus 6.7 months). Meta-analyses confirm nab-paclitaxel outperforms solvent taxanes in pathologic complete response (pCR) rates (17-20% higher) and event-free survival, attributed to improved and reduced Cremophor-related neuropathy/severe adverse events. Vidaza (azacitidine), a hypomethylating agent reactivating tumor suppressor genes via , was marketed by Celgene for higher-risk MDS. FDA-approved on May 19, 2004, for intermediate-2 or high-risk MDS, phase III AZA-001 evidenced median OS of 24.5 months versus 15 months for conventional care (P<0.001), with 47% achieving transfusion independence and delayed AML progression. Expanded 2008 labeling incorporated OS data, positioning it as the first MDS demonstrating survival prolongation over supportive care alone. Hematologic toxicities (cytopenias in 70-90%) are transient and manageable, with benefits outweighing risks in subsets unresponsive to .
DrugKey IndicationsPivotal Efficacy MetricsFDA Approval Year
RevlimidMDS anemia; MM (relapsed, frontline, maintenance); Follicular lymphomaORR 60-75% in MM; PFS doubled vs. placebo in maintenance2005 (MDS); 2006 (MM)
PomalystRelapsed/refractory MM (post-2 therapies)ORR 29%; Median OS 12.7 months2013
AbraxaneMBC; NSCLC; Pancreatic cancerOS 8.5 mo. pancreatic; ORR 33% NSCLC2005 (MBC); 2012 (NSCLC)
VidazaHigher-risk MDSOS 24.5 mo. vs. 15 mo. conventional2004

Immunology and Other Therapeutics

Celgene expanded its portfolio beyond oncology through investments in therapeutics, aiming to mitigate risks associated with reliance on hematologic malignancies and enhance long-term revenue stability via treatments for autoimmune and inflammatory conditions. This diversification included phosphodiesterase-4 (PDE4) inhibitors and other immunomodulatory agents, with clinical evidence demonstrating efficacy in reducing inflammatory symptoms in and related disorders. Otezla (apremilast), a selective PDE4 inhibitor, received U.S. (FDA) approval on March 21, 2014, for adults with active , followed by approval for moderate-to-severe plaque on September 23, 2014. Clinical trials showed apremilast reduced symptoms, with phase 3 data indicating significant improvements in American College of Rheumatology response criteria (e.g., 30% response rates of 38% versus 19% for in patients). By 2018, Otezla generated $1.6 billion in global sales for Celgene, driven by volume growth in and indications, including a 2019 expansion to oral ulcers in . Istodax (romidepsin), a (HDAC) inhibitor, was approved by the FDA on November 5, 2009, for (CTCL) in patients with at least one prior , offering an alternative for relapsed or refractory cases. supported its use in achieving durable responses, with objective response rates around 34% in pivotal trials, though cardiac monitoring was required due to QT prolongation risks. European approval followed in 2012, broadening access, but the peripheral T-cell lymphoma indication was withdrawn in 2022 after post-marketing data review. Efforts in included GED-0301 (mongersen), an oral SMAD7 antisense for , which showed promise in phase 2 trials with remission rates up to 55% at 12 weeks versus 10% for . However, phase 3 studies failed to meet futility endpoints in 2017, leading Celgene to terminate development, highlighting challenges in translating early antisense efficacy to larger populations and informing subsequent degrader technologies. These initiatives contributed to portfolio resilience, with non-oncology products comprising a growing share of revenues pre-acquisition.

Research Pipeline

Pre-Acquisition Developments

In the late 2010s, Celgene's research pipeline emphasized and , with multiple candidates advancing through late-stage clinical trials amid high industry attrition rates. By the end of 2018, the company reported 11 positive Phase III outcomes across , , and , reflecting aggressive in cellular therapies and small-molecule modulators. These efforts built on acquisitions like in 2018 for CAR-T technologies and Receptos in 2015 for (S1P) receptor modulators, positioning Celgene to address unmet needs in relapsed/refractory lymphomas and (MS). However, pharmaceutical development faced empirical risks, with overall success rates from Phase I to approval averaging around 14% across leading firms, driven by Phase II failure rates exceeding 80% due to shortfalls or issues. Celgene's oncology pipeline highlighted lisocabtagene maraleucel (liso-cel, JCAR017), a CD19-directed CAR-T partnered through Juno, with pivotal trials like TRANSCEND NHL 001 initiated in the mid-2010s evaluating it in relapsed/refractory aggressive . Phase II data from 2018 updates demonstrated overall response rates exceeding 70% in heavily pretreated patients, including complete responses in over 50%, though with risks of and neurologic events managed via protocol mitigations. This high-risk approach aligned with Celgene's focus on transformative cellular immunotherapies, where preclinical and early-phase attrition often stemmed from and off-target toxicities, contributing to per-drug approval costs estimated at $2.6 billion when capitalized over failures. In , (RPC1063), an oral S1P1/5 receptor modulator acquired via Receptos, progressed through Phase III trials like RADIANCE (NCT02047734) and (NCT02294058), comparing it to in relapsing MS. Late-2010s data showed annualized relapse rate reductions of 48% and 38% relative to active comparator in these studies, with volume preservation and lesion reduction metrics outperforming placebo-controlled benchmarks from earlier phases, though cardiac monitoring was required due to risks. These results suggested potential advantages over first-generation S1P modulators like in selectivity and tolerability profiles. Celgene's pipeline model thus exemplified the high-reward potential of targeted acquisitions, tempered by the sector's ~$2-3 billion average out-of-pocket and capitalized costs per successful new molecular entity, underscoring the empirical gamble on late-stage validation.

Legacy Impact Post-Acquisition

Following the 2019 acquisition, Celgene's immunomodulatory imide drugs (IMiDs), such as lenalidomide (Revlimid), have informed Bristol Myers Squibb's (BMS) evolution toward next-generation cereblon E3 ligase modulators (CELMoDs), including investigational agents iberdomide and mezigdomide, aimed at enhancing targeted protein degradation for multiple myeloma and lymphoma. These advancements build directly on Celgene's foundational IMiD research, integrating with BMS's platform for molecular glues and degraders to pursue deeper remissions in relapsed/refractory settings. Celgene's CAR-T legacy, via its Juno acquisition, has sustained momentum in BMS's cell therapy portfolio, exemplified by idecabtagene vicleucel (Abecma), which received U.S. FDA approval for earlier-line use in triple-class exposed relapsed/refractory on April 4, 2024, and authorization for similar indications on March 20, 2024. Further label updates in June 2025 streamlined patient monitoring requirements, reflecting combined resources accelerating regulatory progress and manufacturing scale-up without evident strategic reversals. Integration synergies, realizing $2.5 billion in annual cost savings by 2021, have redirected resources to depth, yielding nine product launches from Celgene assets in the immediate post-merger years, including luspatercept and , while sustaining R&D without acquisition divestitures or pipeline abandonments. This has preserved specialized /oncology expertise amid efficiencies, enabling 2024-2025 advancements like long-term survival data presentations for cell therapies at the American Society of Hematology meeting.

Financial Overview

Revenue Growth and Key Metrics

Celgene's revenue expanded substantially from $3.05 billion in 2010 to $15.28 billion in , driven primarily by strong sales of its flagship immunomodulatory drugs. This growth corresponded to a (CAGR) of approximately 22% over the period, underscoring the commercial success of its oncology-focused portfolio amid expanding indications and . Revlimid (), the company's cornerstone product, accounted for the majority of this increase, generating over $51 billion in worldwide net from to 2018, with U.S. sales comprising about $32 billion of that total. Profitability metrics remained robust, with net profit margins fluctuating between 17% and 26% during the decade, recovering to 26.5% in 2018 on of $4.05 billion. Operating margins ranged from 24% to 38%, reflecting efficient scaling of high-margin products like Revlimid, which benefited from limited generic competition due to regulatory and protections. Gross margins consistently exceeded 95%, supported by the low variable costs associated with branded biologics and small-molecule therapies post-approval. Research and development (R&D) investments, averaging 30-37% of in later years, fueled expansion and acquisitions that proved accretive to earnings. For instance, the 2015 acquisition of Receptos for $7.2 billion enhanced Celgene's assets, including , and was projected to be earnings-per-share accretive starting in 2018, bolstering long-term diversification. These investments, combined with strength, drove confidence, culminating in a pre-acquisition market capitalization peak exceeding $70 billion in 2015, which later moderated but highlighted the perceived value of Celgene's innovation-driven model.

Investments and Valuation

Celgene pursued an aggressive acquisition strategy between 2007 and 2018, investing over $25 billion in to bolster its pipeline and therapeutic portfolio. Key deals included the $2.9 billion purchase of Pharmion Corporation in 2008, which added Vidaza to its offerings; the $7.2 billion acquisition of Receptos in 2015, securing Otezla for treatment; the $2.4 billion deal for Nogra Pharma in 2016, enhancing its assets; and the $7 billion buyout of Impact Biomedicines in 2018, targeting for myelofibrosis. These investments generated substantial (NPV) from integrated pipeline assets, with Otezla alone contributing peak annual sales exceeding $2 billion by 2019, demonstrating returns that offset risks of integration and payments. Complementing M&A, Celgene executed buybacks and initiated to return capital to shareholders, signaling financial discipline amid growth investments. The company authorized multiple repurchase programs, including a $5 billion plan in 2017, repurchasing shares to enhance while maintaining R&D funding. , starting modestly in 2016 at $0.04 per share quarterly, rose to $0.11 by 2018, reflecting confidence in cash flows from patented drugs like Revlimid, which generated monopoly-like returns to future rather than short-term distributions. Bristol-Myers Squibb's $74 billion acquisition of Celgene in November 2019 traded at approximately 5x trailing twelve-month revenue and 12.6x EBITDA, benchmarks aligned with peer biotech deals but elevated by Celgene's pipeline NPV estimates of $20-30 billion from late-stage assets. Street projections valued Celgene's pipeline revenues at $5 billion by 2023 alone, implying multiples of 15-20x forward sales when discounted for risk-adjusted approvals. This premium proved justified by post-merger performance through 2025, as BMS realized $2.5 billion in annual synergies, diversified revenues to $45-48 billion, and delivered total shareholder returns exceeding 50% from deal announcement lows, driven by integrated IP-driven cash flows funding sustained R&D. Such outcomes underscore how temporary patent protections enable high-margin reinvestment, countering critiques of capital allocation as overly speculative by evidencing causal links between acquisitions and long-term value creation.

Antitrust and Competition Issues

In November 2019, the U.S. Federal Trade Commission (FTC) approved Bristol-Myers Squibb's (BMS) $74 billion acquisition of Celgene subject to the divestiture of Celgene's psoriasis drug Otezla (apremilast) to Amgen for $13.4 billion, addressing concerns that the merger would reduce competition in the oral psoriasis treatment market. The FTC's consent agreement required the divestiture within ten days of closing to maintain competitive alternatives, but found no broader monopoly risks from the deal after this remedy. The acquisition closed on November 20, 2019, without additional antitrust blocks. Canada's investigated Celgene, alongside and , starting around 2016 for alleged abuse of dominance through policies restricting generic manufacturers' access to branded drug samples needed for testing. In December 2018, the Bureau discontinued the inquiry, concluding there was insufficient evidence that the practices contravened the or substantially lessened competition. A 2022 position statement reaffirmed the closure, noting the policies aimed at preventing diversion for unapproved uses rather than blocking generics. Celgene faced U.S. antitrust lawsuits alleging "pay-for-delay" settlements with generic firms, including Mylan and Dr. Reddy's, that purportedly delayed generic entry for Revlimid (lenalidomide) by providing reverse payments or other incentives in exchange for patent challenges being dropped. In August 2019, Celgene settled two such class-action suits for a combined $117 million without admitting liability, just prior to the BMS merger, with courts later dismissing related claims on statute-of-limitations grounds or lack of anticompetitive effect. Proponents of the settlements argued they facilitated additional safety data collection on Revlimid's risks, such as secondary malignancies, extending beyond initial FDA approvals, though critics from the FTC and others viewed such deals as presumptively anticompetitive under Actavis precedents. No FTC enforcement action resulted, and generic entry began in 2022 after patent expirations.

Fraud and Compliance Allegations

In 2016, a whistleblower lawsuit alleged that Celgene Corporation violated the Anti-Kickback Statute by donating millions to patient assistance charities, such as the Patient Access Network Foundation and HealthWell Foundation, to subsidize copayments for its drug Revlimid, thereby inducing Medicare and other payers to cover the costs and generating billions in reimbursements for the company. The U.S. Department of Justice responded by issuing a to Celgene regarding its relationships with these charities, which provide financial aid to patients facing high out-of-pocket costs for specialty drugs. Such programs are commonplace in the to enhance patient access amid rising copay burdens, though critics argue they can function as disguised rebates favoring specific manufacturers' products over competitors. Separately, in the , federal investigations probed Celgene for off-label promotion of Revlimid and Thalomid, stemming from a 2010 whistleblower complaint under the False Claims Act, which claimed the company marketed the drugs for unapproved uses like first-line treatment of , leading to improper reimbursements from programs. These allegations were resolved in 2017 through a $280 million settlement with the DOJ and participating states, including $259.3 million to the federal , without Celgene admitting liability or wrongdoing. In response to these matters, Celgene overhauled its compliance framework, incorporating strengthened internal controls, employee training on promotion standards, and monitoring of third-party interactions, measures typical in pharmaceutical settlements to align with FDA and DOJ expectations. No systemic convictions followed, and the absence of major subsequent enforcement actions prior to the company's 2019 acquisition by Bristol-Myers Squibb indicates these reforms mitigated risks effectively, prioritizing targeted governance over broader regulatory interventions that might hinder legitimate patient support initiatives.

Drug Pricing Practices and Disputes

Celgene's flagship drug Revlimid (), approved for in 2006, saw its U.S. rise from approximately $8,000 per month in 2010 to $16,691 per month by 2016, reflecting average annual increases of about 7.85% during that period. In 2017 alone, Celgene implemented multiple hikes totaling nearly 20%, pushing the monthly to over $16,000 amid criticism from lawmakers and advocates for exacerbating affordability issues without corresponding evidence of enhanced clinical value. These increases aligned with industry norms for high-margin drugs but drew scrutiny for outpacing inflation and general medical cost trends by factors of 4 to 5 times. Net prices realized by Celgene after rebates, discounts, and patient assistance were lower than list prices, though still subject to upward trends; for instance, Revlimid's net U.S. price per pill rose from $294 in 2009 to $598 in 2018, representing roughly a doubling while list prices more than tripled. Negotiated discounts in commercial markets averaged around 5% for lenalidomide, with Celgene's copay assistance programs—such as RevAssist—covering out-of-pocket costs for eligible patients but comprising only 0.16% of net U.S. revenue from 2011 to 2018. Celgene participated in the 340B Drug Pricing Program, providing discounted Revlimid to eligible safety-net providers, and offered free medication through the Celgene Patient Support Foundation for uninsured or underinsured patients meeting income criteria, mitigating some access barriers despite high list pricing. Economic analyses have generally affirmed Revlimid's cost-effectiveness in treatment. maintenance therapy post-transplant yielded an incremental cost-utility ratio below $200,000 per (QALY) gained in U.S. models, driven by extended averaging 1-2 additional years. Compared to alternatives like bortezomib-based regimens, lenalidomide reduced per-patient monthly hospitalization costs by approximately €360 (about $400), reflecting fewer inpatient stays due to delayed disease progression and lower complication rates. Independent assessments, such as those from the Institute for Clinical and Economic Review (ICER), indicated that while list prices exceeded 100,000−100,000-150,000 per QALY thresholds, negotiated net prices often aligned with value-based benchmarks when accounting for survival gains of 5.72 QALYs versus observation alone. Drug pricing disputes intensified around allegations of artificial generic delays via patent litigation and risk evaluation and mitigation strategies (REMS), which critics claimed prolonged Revlimid's monopoly and sustained high prices. In 2017, Connecticut Attorney General George Jepsen joined a multistate coalition in federal antitrust litigation accusing pharmaceutical firms, including Celgene, of industry-wide tactics to impede generic entry through sham suits and pay-for-delay settlements, though Celgene defended its actions as legitimate enforcement of valid secondary patents upheld in court. These challenges were counterbalanced by the need to recoup substantial R&D investments; average capitalized costs for bringing a new drug to market exceeded $2.3 billion in the 2020s, with oncology agents like lenalidomide requiring extensive clinical trials to demonstrate efficacy in rare, aggressive indications. Broader societal returns from Revlimid included indirect savings from reduced healthcare utilization; lenalidomide's in frontline and maintenance correlated with billions in averted hospitalizations across myeloma patients, as outpatient regimens minimized acute events compared to pre-lenalidomide standards. Such outcomes underscored causal links between incentives—sustained by flexibility—and net economic value, even as critiques from sources like congressional reports highlighted profit prioritization over immediate affordability. Post-acquisition by in 2019, continuity faced ongoing federal scrutiny, but empirical data on QALY gains and offsets supported the drug's in advancing causal realism over unsubstantiated gouging claims.

References

  1. https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company/default.aspx
  2. https://www.lobbyfacts.eu/datacard/celgene?rid=37955905654-37
  3. https://www.statnews.com/2019/01/22/celgene-legacy-chutzpah-science-drug-pricing/
  4. https://golden.com/wiki/Celgene-RE4ZRW
  5. https://www.biospace.com/celgene-the-good-the-bad-and-the-ugly
  6. https://www.patientsforaffordabledrugs.org/2019/07/24/celgene-lawsuit/
  7. https://www.bms.com/about-us/our-company/history-timeline.html
  8. https://www.bloomberg.com/news/articles/2016-08-01/celgene-accused-of-using-charities-in-scheme-to-gain-billions
  9. https://www.hausfeld.com/en-de/news/hausfeld-announces-55-million-settlement-in-antitrust-class-action-against-celgene
  10. https://pitchbook.com/profiles/company/41333-95
  11. https://www.encyclopedia.com/books/politics-and-business-magazines/celgene-corporation
  12. https://www.company-histories.com/Celgene-Corporation-Company-History.html
  13. https://www.reuters.com/article/business/celgene-to-buy-receptos-for-72-billion-gains-promising-drug-idUSKCN0PO2OA/
  14. https://investors.bms.com/iframes/press-releases/press-release-details/2019/Bristol-Myers-Squibb-to-Acquire-Celgene-to-Create-a-Premier-Innovative-Biopharma-Company/default.aspx
  15. https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Completes-Acquisition-of-Celgene-Creating-a-Leading-Biopharma-Company/default.aspx
  16. https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Shareholders-Approve-Celgene-Acquisition/default.aspx
  17. https://www.fiercepharma.com/pharma/bristol-celgene-ceos-explain-rationale-behind-74b-megadeal-at-jpm
  18. https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Files-Investor-Presentation-and-Board-of-Directors-Sends-Letter-to-Shareholders-Regarding-Pending-Transaction-with-Celgene/default.aspx
  19. https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Receives-Clearance-from-US-Federal-Trade-Commission-for-Celgene-Acquisition/default.aspx
  20. https://www.ftc.gov/news-events/news/press-releases/2020/01/ftc-approves-final-order-requiring-bristol-myers-squibb-company-celgene-corporation-divest-psoriasis
  21. https://www.ftc.gov/legal-library/browse/cases-proceedings/191-0061-bristol-myers-squibb-company-celgene-corporation-matter
  22. https://blog.inovia.bio/inovia-bio-insights/bristol-myers-squibbs-acquisition-of-celgene-a-5-year-retrospective-success-synergies-and-strategic-growth
  23. https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025/default.aspx
  24. https://seekingalpha.com/article/4807729-bristol-myers-q2-earnings-review-solid-quarter-but-incoming-cmo-must-fix-pipeline
  25. https://njbiz.com/barer-steps-down-as-celgene-ceo-to-become-executive-chairman/
  26. https://www.tevapharm.com/our-company/corporate-governance/board-of-directors/dr-sol-j-barer/
  27. https://www.reuters.com/article/idUKTRE7135HJ20110204
  28. https://drug-dev.com/celgene-had-the-highest-rd-spend-in-2018/
  29. https://www.prnewswire.com/news-releases/bio-pharma-giant----celgene----settles-case-alleging-marketing-violations-for-280-million-300494044.html
  30. https://www.bloomberg.com/profile/person/3169517
  31. https://docs.house.gov/meetings/GO/GO00/20200930/111055/HHRG-116-GO00-Wstate-AllesM-20200930.pdf
  32. https://www.casemine.com/judgement/us/61e90646b50db931edead65f
  33. https://www.sec.gov/Archives/edgar/data/816284/000081628419000020/celgenecorp10-ka.htm
  34. https://www.cancernetwork.com/view/celgene-acquire-pharmion
  35. https://www.fiercebiotech.com/biotech/celgene-to-acquire-receptos-advancing-leadership-immune-inflammatory-diseases
  36. https://www.npr.org/sections/health-shots/2018/05/17/571986468/how-a-drugmaker-gamed-the-system-to-keep-generic-competition-away
  37. https://news.bms.com/news/details/2019/Bristol-Myers-Squibb-Issues-Statement-on-Celgenes-Settlement-with-Alvogen-on-Revlimid-Patent-Litigation/default.aspx
  38. https://www.fiercepharma.com/pharma/organizational-changes-strengthen-leadership-team-and-position-celgene-for-long-term-growth
  39. https://www.nature.com/articles/leu2012119
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7298168/
  41. https://pubmed.ncbi.nlm.nih.gov/24166296/
  42. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-global-strategic-collaboration-celgene
  43. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-and-celgene-corporation-enter-agreement-co-develop
  44. https://pubs.acs.org/doi/10.1021/acs.biochem.2c00245
  45. https://cen.acs.org/articles/96/i11/Interest-targeted-protein-degraders-continues-in-new-partnership-between-Celgene-and-Vividion.html
  46. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=129682
  47. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021880s000_RevlimidTOC.cfm
  48. https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid
  49. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=147701
  50. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pomalidomide-kaposi-sarcoma
  51. https://www.biospace.com/celgene-corporation-announces-pomalyst-granted-breakthrough-therapy-designation-from-fda-for-hiv-positive-and-negative-kaposi-sarcoma
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC5013840/
  53. https://www.fda.gov/media/95302/download
  54. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021880s057lbl.pdf
  55. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenalidomide-follicular-and-marginal-zone-lymphoma
  56. https://www.biospace.com/abbvie-s-humira-remains-the-top-selling-prescription-for-2018
  57. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000Approv.pdf
  58. https://ecancer.org/en/news/3803-fda-aproves-pomalidomide-for-multiple-myeloma-where-two-prior-therapies-have-failed
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4093466/
  60. https://www.cancernetwork.com/view/fda-approves-abraxane-metastatic-breast-cancer
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC7863369/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC2948932/
  63. https://www.fiercebiotech.com/biotech/vidaza-r-receives-expanded-fda-approval-to-include-overall-survival-higher-risk-mds
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC4086808/
  65. https://www.biopharmadive.com/news/celgenes-otezla-quarter-earnings-ozanimod/441404/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC4665061/
  67. https://www.drugs.com/history/otezla.html
  68. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205437Orig1s000MedR.pdf
  69. https://www.sec.gov/Archives/edgar/data/318154/000119312519228830/d787825dex991.htm
  70. https://www.biospace.com/fda-approves-otezla-apremilast-for-the-treatment-of-oral-ulcers-associated-with-behcet-s-disease
  71. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=193404
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC3163831/
  73. https://www.federalregister.gov/documents/2022/05/09/2022-09889/celgene-corporation-and-teva-pharmaceutical-industries-ltd-withdrawal-of-approval-of-peripheral
  74. https://www.nejm.org/doi/full/10.1056/NEJMoa1407250
  75. https://www.healio.com/news/gastroenterology/20171020/celgene-halts-mongersen-trials-in-crohns-disease
  76. https://s21.q4cdn.com/104148044/files/doc_presentations/2019/BMY-Transaction-Fact-Sheet-03-25-19-01074879-8xA26CA.PDF
  77. https://www.sec.gov/Archives/edgar/data/816284/000114420419004124/tv512163_425.htm
  78. https://www.sciencedirect.com/science/article/pii/S1359644625000042
  79. https://www.knowledgeportalia.org/r-d-time-and-success-rate
  80. https://www.drugsincontext.com/wp-content/uploads/2019/02/dic.212567.pdf
  81. https://lifescivc.com/2014/11/a-billion-here-a-billion-there-the-cost-of-making-a-drug-revisited/
  82. https://clinicaltrials.gov/study/NCT02047734
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC7768354/
  84. https://www.science.org/content/blog-post/drug-development-costs-revisited
  85. https://www.bms.com/life-and-science/science/pioneering-next-gen-therapies-for-blood-cancer.html
  86. https://news.bms.com/news/details/2024/Bristol-Myers-Squibbs-Abecma-idecabtagene-vicleucel-Becomes-First-CAR-T-Cell-Therapy-Approved-in-the-European-Union-in-Earlier-Lines-for-Triple-Class-Exposed-Relapsed-and-Refractory-Multiple-Myeloma/default.aspx
  87. https://www.bigmoleculewatch.com/2024/04/11/fda-approves-bms-and-jj-car-t-cell-therapies-for-the-earlier-treatment-of-multiple-myeloma/
  88. https://news.bms.com/news/details/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx
  89. https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Highlights-Progress-of-Cell-Therapy-Portfolio-at-ASH-2024-with-Long-Term-Survival-Data-and-Results-from-Expanding-Pipeline/default.aspx
  90. https://www.statista.com/statistics/274268/revenue-and-net-income-of-biotech-company-celgene/
  91. https://mlq.ai/stocks/CELG/revenue-growth/
  92. https://oversightdemocrats.house.gov/sites/evo-subsites/democrats-oversight.house.gov/files/Celgene%2520BMS%2520Staff%2520Report%252009-30-2020.pdf
  93. https://www.stock-analysis-on.net/NASDAQ/Company/Celgene-Corp/Ratios/Adjusted-Ratios
  94. https://www.stock-analysis-on.net/NASDAQ/Company/Celgene-Corp/Ratios/Profitability/Quarterly-Data
  95. https://csimarket.com/stocks/Profitability.php?code=CELG
  96. https://www.financierworldwide.com/fw-news/2015/7/16/celgene-and-receptos-agree-72bn-merger
  97. https://www.biopharmadive.com/news/bristol-myers-buy-celgene-74-billion-pharma-deal/545184/
  98. https://tracxn.com/d/acquisitions/acquisitions-by-celgene/__dQ8Y8yeau1HYkrah65JG8Uh-usM_BhNqQeIMzX0wUsU
  99. https://www.sec.gov/Archives/edgar/data/816284/000095012308001878/y49949e10vk.htm
  100. https://www.nasdaq.com/market-activity/stocks/celg.rt/dividend-history
  101. https://www.dividend.com/stocks/health-care/biotech-pharma/biotech/celg-celgene-corporation/
  102. https://research.cbs.dk/files/62174850/881337_Master_Thesis_Alena_Marie_Abb_Janina_Bartkewitz.pdf
  103. https://www.bourne-partners.com/deal-profile/deal-profile-bms-celgene/
  104. https://seekingalpha.com/article/4832767-bristol-myers-squibb-this-16-percent-fcf-yield-is-the-best-value-in-healthcare
  105. https://www.ftc.gov/news-events/news/press-releases/2019/11/ftc-requires-bristol-myers-squibb-company-celgene-corporation-divest-psoriasis-drug-otezla-condition
  106. https://www.ftc.gov/system/files/documents/cases/bms-celgene_aac.pdf
  107. https://www.federalregister.gov/documents/2019/12/03/2019-26074/bristol-myers-squibb-company-and-celgene-corporation-analysis-of-agreement-containing-consent-orders
  108. https://competition-bureau.canada.ca/en/how-we-foster-competition/education-and-outreach/position-statements/investigation-alleged-practices-celgene-pfizer-and-sanofi
  109. https://www.canada.ca/en/competition-bureau/news/2018/12/competition-bureau-completes-abuse-of-dominance-investigation-into-practices-of-celgene-pfizer-and-sanofi.html
  110. https://www.fiercepharma.com/pharma/celgene-to-pay-combined-117m-to-settle-antitrust-suits-mylan-union
  111. https://www.ftc.gov/news-events/topics/competition-enforcement/pay-delay
  112. https://www.congress.gov/crs-product/R46679
  113. https://www.biopharmadive.com/news/celgene-facing-charity-related-kickback-allegations/423702/
  114. https://www.fiercepharma.com/pharma/doj-issues-subpoena-to-celgene-as-feds-cast-a-wider-net-assistance-program-probe
  115. https://www.justice.gov/usao-cdca/pr/celgene-agrees-pay-280-million-resolve-fraud-allegations-related-promotion-cancer-drugs
  116. https://www.reuters.com/article/business/celgene-to-pay-280-million-to-settle-off-label-marketing-case-idUSKBN1AA2P9/
  117. https://www.genengnews.com/news/celgene-agrees-to-pay-280m-in-whistleblower-suit-settlement/
  118. https://www.fool.com/investing/2017/10/25/price-hikes-insulate-celgene-from-a-failure.aspx
  119. https://www.fiercepharma.com/pharma/celgene-takes-its-most-aggressive-price-hikes-revlimid-pomalyst-yet-analyst
  120. https://www.propublica.org/article/revlimid-price-cancer-celgene-drugs-fda-multiple-myeloma
  121. https://rollcall.com/2020/09/30/internal-documents-show-drugmakers-reliance-on-us-price-hikes/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC11771817/
  123. https://www.nbcnews.com/health/health-news/high-drug-prices-driven-profits-house-panel-report-finds-n1241589
  124. https://www.bmsaccesssupport.com/co-pay-financial-assistance
  125. https://www.hematology.org/education/clinicians/drug-resources/high-cost-hematologic-drug-access/lenalidomide
  126. https://pubmed.ncbi.nlm.nih.gov/31150015/
  127. https://www.sciencedirect.com/science/article/pii/S0006497119395849
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC5488111/
  129. https://icer.org/news-insights/press-releases/icer-releases-evidence-report-on-treatments-for-multiple-myeloma/
  130. https://portal.ct.gov/AG/Press-Releases-Archived/2017-Press-Releases/AG-Jepsen-Leads-Coalition-in-New-Expanded-Complaint-in-Federal-Generic-Drug-Antitrust-Lawsuit
  131. https://www.hbsslaw.com/cases/revlimid-antitrust
  132. https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/measuring-return-from-pharmaceutical-innovation.html
  133. https://www.statista.com/topics/6755/pharmaceutical-research-and-development-randd/
  134. https://www.wifor.com/uploads/2020/07/20200630_The-Social-Impact-of-Lenalidomide_Project-report_WifOR_final.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.